AVITA Medical, Inc.
NASDAQ:RCELMedical - Devices
+$0.00 today
- Market cap
- $418.11M
- Beta
- 1.86
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$148.45
Volume 0.72M
Average 0.24M
RCEL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
AVITA Medical, Inc.NASDAQ: RCEL
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$8.57M, compared with -$12.1M a year earlier. Trailing-twelve-month EBITDA was -$37.72M.
Context
- EBITDA amounted to 55.3% of revenue in FY2025, down 30.8 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$19.73M (+50.2%) for the fiscal year ending Dec 2026, a step up from the +28.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.57M+11.7% QoQ
- Last fiscal yearDec 2025
- -$39.59M+28.4% YoY
- LTMMar 2026
- -$37.72M+25.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +29.1% | +14.1% | -15.1 pp |
| 1 year | +28.4% | +50.2% | +21.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (39.59M) USD
- Year-over-year change
- +28.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.59M) | +28.4% |
| FY2024 | 2024-12-31 | (55.3M) | -64.9% |
| FY2023 | 2023-12-31 | (33.54M) | -28.8% |
| FY2022 | 2022-12-31 | (26.05M) | -6.7% |
| FY2021 | 2021-12-31 | (24.4M) | — |
EBITDA vs competitors
How RCEL compares with its peers on the latest reported figures
- RCEL's LTM Mar 2026 EBITDA of -$37.72M is the 7th highest of the 9 companies compared; the peer median is -$25.32M.
- Its year-over-year change of +25.1% is the 5th highest of 9, against a peer median of +21.6%.
- EBITDA amounts to 52.1% of revenue for RCEL, versus a peer median of 216.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.91M | -15.8% | -12.5% | 15.1% | |
| LTM Mar 2026 | $11.81M | +465.2% | — | 9.7% | |
| LTM Mar 2026 | -$2.44M | +81.8% | — | 4.4% | |
| LTM Mar 2026 | -$24M | +7.8% | — | 337.0% | |
| LTM Mar 2026 | -$26.64M | -14.1% | — | — | |
| LTM Mar 2026 | -$33.15M | +15.7% | — | 216.2% | |
| LTM Mar 2026 | -$37.72M | +25.1% | — | 52.1% | |
| LTM Mar 2026 | -$44.12M | +27.6% | — | 859.3% | |
| LTM Mar 2026 | -$46.23M | +30.8% | — | 4623.1% | |
| Peer median (excluding RCEL) | -$25.32M | +21.6% | -12.5% | 216.2% | |
Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.03M | 34.42M | 50.14M | 64.25M | 71.61M |
| Cost of Revenue | 6.1M | 6.04M | 7.78M | 9.09M | 12.79M |
| Gross Profit | 26.92M | 28.38M | 42.36M | 55.16M | 58.82M |
| Gross Margin | 81.5% | 82.4% | 84.5% | 85.8% | 82.1% |
| Research & Development | 15.67M | 13.86M | 20.82M | 20.36M | 20.84M |
| Selling, General & Admin | 37.21M | 45.24M | 65.63M | 91.39M | 79.91M |
| Operating Expenses | 52.04M | 55.89M | 85.02M | 111.75M | 100.75M |
| Depreciation & Amortization | 673K | 568K | 632K | 1.13M | 2.35M |
| EBITDA | (24.4M) | (26.05M) | (33.54M) | (55.3M) | (39.59M) |
| EBITDA Margin | -73.9% | -75.7% | -66.9% | -86.1% | -55.3% |
| Operating Income | (25.12M) | (27.51M) | (42.66M) | (56.59M) | (41.93M) |
| Operating Margin | -76.1% | -79.9% | -85.1% | -88.1% | -58.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 29K | 16K | 1.14M | 5.36M | 5M |
| Other Income / Expenses | 18K | 876K | 7.34M | (5.2M) | (6.64M) |
| Income Before Tax | (25.1M) | (26.63M) | (35.32M) | (61.79M) | (48.58M) |
| Pre-Tax Margin | -76.0% | -77.4% | -70.4% | -96.2% | -67.8% |
| Income Tax Expense | 42K | 36K | 66K | 54K | 11K |
| Net Income | (25.14M) | (26.67M) | (35.38M) | (61.85M) | (48.59M) |
| Net Margin | -76.1% | -77.5% | -70.6% | -96.3% | -67.8% |
| EPS (Basic) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| EPS (Diluted) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| Weighted Avg Shares | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
| Weighted Avg Shares (Diluted) | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
AVITA Medical, Inc.
NASDAQ:RCEL
Intrinsic Alpha fair value
Locked
Current Price
$16.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.